RegCell, a Japan-based biotechnology company, announced on Thursday that it has named Michael V McCullar, PhD., MBA as its new president, chief executive officer, and representative director.

Dr McCullar has a range of experience in the biotech and pharmaceutical industries, covering over two decades. He formerly served as the CEO of OnQuality Pharmaceuticals, chief operating officer at Tolero Pharmaceuticals and senior vice president of Business Development at Astex Pharmaceuticals. He has held various high-level executive positions at SuperGen.

Dr McCullar, said, 'I am honoured to join this remarkable team at an exciting time for RegCell as we prepare to enter the clinical stage and to support the company's mission to discover innovative treatments for autoimmune diseases. In an era where the increasingly aging population is facing an escalating burden of autoimmune disorders, Treg-based cellular therapies are opening the doors to exciting new treatment possibilities. I look forward to contributing my expertise towards validating the promising potential of our regulatory T cell platform and expanding our U.S. footprint as we advance our programs towards the clinic in 2024.'